From 1990 to 2000, Microsoft Windows held a dominant monopoly position in personal computer operating systems. The company set prices without a close competitive alternative constraining them, bundled products in ways that leveraged this position, and earned returns on invested capital far above any competitive benchmark. The 1998 Department of Justice antitrust suit — and the evidence compiled in it — documented exactly what monopoly economics predicts: a single seller with market power producing at prices well above marginal cost, restricting competition to preserve its position.
In plain terms
A monopoly is a market structure in which a single firm is the sole seller of a product that has no close substitutes. Three characteristics define it:
- One seller: the firm is the entire market on the supply side.
- No close substitutes: buyers cannot readily switch to an alternative good to avoid the monopolist's price.
- Barriers to entry: something prevents competitors from entering and challenging the monopolist's position.
Unlike a competitive price-taker, the monopolist faces the downward-sloping market demand curve directly. It is a price-maker — it chooses a price (or equivalently, a quantity) and the demand curve determines how much buyers will purchase.
Why it works this way
A monopolist maximizes profit by producing where MR = MC, just like any other firm. But because it faces a downward-sloping demand curve, MR < P. The profit-maximizing output is therefore less than the output where P = MC — the competitive level. At the monopoly quantity, the price charged (from the demand curve) exceeds marginal cost.
This produces three outcomes compared to perfect competition:
- Higher price: P > MC, a markup above competitive pricing
- Lower output: the monopoly underproduces relative to the social optimum
- Deadweight loss: the units between the monopoly output and the competitive output have MB > MC but go unproduced — value that consumers and society don't capture
The DOJ Antitrust Division's enforcement record documents the prices and output levels in monopolized markets that motivated intervention — consistently showing the above-MC pricing pattern that theory predicts.
A real example
Patent-protected pharmaceuticals operate as temporary monopolies. The FDA's drug pricing data shows that brand-name drugs under patent sell at prices dramatically above their marginal production cost — the explicit policy mechanism that grants innovators monopoly profits for a period to incentivize R&D investment. When patents expire, generic entry drives prices toward marginal cost within months — restoring competitive conditions.
Why it matters
Monopoly is the primary market failure in goods markets. Governments respond through antitrust enforcement (preventing monopolization), rate regulation (for natural monopolies), and time-limited patents (balancing innovation incentives against monopoly costs). Understanding monopoly pricing, deadweight loss, and barriers to entry is the foundation of all market power analysis.
